NASDAQ: MDGSMedigus Ltd Stock
$4.87-0.27 (-5.25%)
Updated May 26, 2023
MDGS Price
$4.87
Fair Value Price
$20.78
Market Cap
$8.04M
52 Week Low
$4.02
52 Week High
$13.05
P/E
-0.81x
P/B
0.21x
P/S
0.08x
PEG
N/A
Dividend Yield
17.47%
Revenue
$91.86M
Earnings
-$9.82M
Gross Margin
15.7%
Operating Margin
-8.05%
Profit Margin
-10.7%
Debt to Equity
1.1
Operating Cash Flow
-$6M
Beta
0.46
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MDGS Overview
Medigus Ltd., a technology-based company, provides medical-related devices and products in the United States, Europe, China, Israel, and internationally. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease. The company also develops biological gels to protect patients against biological threats and reduce the intrusion of allergens and viruses through the upper airways and eye cavities. In addition, it develops, markets, and distributes software for internet users; and operates online stores for the sale of various consumer products on the Amazon online marketplace, as well as an online event management and ticketing platform. Further, the company develops, produces, and markets miniaturized imaging equipment, visualization solutions, and resistant cameras; electric vehicles; and wireless vehicle battery charging technologies. Medigus Ltd. was incorporated in 1999 and is headquartered in Tel Aviv-Yafo, Israel.
Zen Score
–
Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MDGS scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MDGS ($4.87) is undervalued by 76.59% relative to our estimate of its Fair Value price of $20.78 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
MDGS ($4.87) is significantly undervalued by 76.59% relative to our estimate of its Fair Value price of $20.78 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
MDGS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more MDGS due diligence checks available for Premium users.
Be the first to know about important MDGS news, forecast changes, insider trades & much more!
MDGS News
Valuation
MDGS fair value
Fair Value of MDGS stock based on Discounted Cash Flow (DCF)
Price
$4.87
Fair Value
$20.78
Undervalued by
76.57%
MDGS ($4.87) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MDGS ($4.87) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MDGS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MDGS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.81x
Industry
751.36x
Market
54.23x
MDGS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.21x
Industry
3.87x
MDGS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MDGS's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
MDGS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MDGS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$97.7M
Liabilities
$43.0M
Debt to equity
1.1
MDGS's short-term assets ($52.26M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MDGS's short-term assets ($52.26M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MDGS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MDGS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
MDGS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MDGS vs Medical Device Stocks
Medigus Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.